Trastuzumab deruxtecan + Durvalumab
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Invasive Breast Cancer
Conditions
Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
Trial Timeline
May 4, 2023 → Dec 1, 2032
NCT ID
NCT05795101About Trastuzumab deruxtecan + Durvalumab
Trastuzumab deruxtecan + Durvalumab is a phase 2 stage product being developed by Daiichi Sankyo for Invasive Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05795101. Target conditions include Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer.
What happened to similar drugs?
4 of 20 similar drugs in Invasive Breast Cancer were approved
Approved (4) Terminated (2) Active (15)
🔄Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05795101 | Phase 2 | Recruiting |
Competing Products
20 competing products in Invasive Breast Cancer